Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

Blood

Volumn 124, Issue 9, 2014, Pages 1460-1472

  Kiel, Mark J ^a   Velusamy, Thirunavukkarasu ^a   Rolland, Delphine ^a   Sahasrabuddhe, Anagh A ^a   Chung, Fuzon ^a   Bailey, Nathanael G ^a   Schrader, Alexandra ^b   Li, Bo ^a   Li, Jun Z ^a   Ozel, Ayse B ^a   Betz, Bryan L ^a   Miranda, Roberto N ^c   Medeiros, L Jeffrey ^c   Zhao, Lili ^a   Herling, Marco ^b   Lim, Megan S ^a   Elenitoba Johnson, Kojo S J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; INTERLEUKIN 2 RECEPTOR GAMMA; JANUS KINASE 1; JANUS KINASE 3; PIMOZIDE; STAT5B PROTEIN; TRANSCRIPTION FACTOR EZH2; ATM PROTEIN, HUMAN; DNA; IL2RG PROTEIN, HUMAN; JAK1 PROTEIN, HUMAN; JAK3 PROTEIN, HUMAN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FRAMESHIFT MUTATION; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INDEL MUTATION; JURKAT CELL LINE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; T CELL LEUKEMIA; T CELL PROLYMPHOCYTIC LEUKEMIA; VERY ELDERLY; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CELL DEATH; CHEMICAL STRUCTURE; CHEMISTRY; COHORT ANALYSIS; COMPUTER SIMULATION; COPY NUMBER VARIATION; DNA SEQUENCE; DRUG EFFECTS; EXOME; GENETICS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; TUMOR CELL CULTURE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BASE SEQUENCE; CELL DEATH; COHORT STUDIES; COMPUTER SIMULATION; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXOME; FEMALE; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; JANUS KINASE 1; JANUS KINASE 3; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PIMOZIDE; PROTEIN CONFORMATION; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; STAT5 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84907317719     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-559542     Document Type: Article

References (50)

1. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78(12): 3269-3274.
2. Hopfinger G, Busch R, Pflug N, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013;119(12):2258-2267.
3. Dearden CE. T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma. 2009;(9)Suppl 3: S239-S243.
4. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA. 1994; 91(26):12530-12534.
5. Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM. Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA. 1999;96(6):2949-2951.
6. Fisch P, Forster A, Sherrington PD, Dyer MJ, Rabbitts TH. The chromosomal translocation t(X;14)(q28;q11) in T-cell pro-lymphocytic leukaemia breaks within one gene and activates another. Oncogene. 1993;8(12):3271-3276.
7. Stern MH, Soulier J, Rosenzwajg M, et al. MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene. 1993;8(9):2475-2483.
8. Vorechovsky I, Luo L, Dyer MJ, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet. 1997;17(1):96-99.
9. Stoppa-Lyonnet D, Soulier J, Laugé A, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91(10): 3920-3926.
10. Stilgenbauer S, Schaffner C, Litterst A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 1997; 3(10):1155-1159.
11. Gritti C, Dastot H, Soulier J, et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood. 1998;92(2):368-373.
12. Virgilio L, Lazzeri C, Bichi R, et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA. 1998;95(7): 3885-3889.
13. Bellanger D, Jacquemin V, Chopin M, et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia. 2014; 28(2):417-419.
14. Isaacson PG, Catovsky D, Müller-Hermelink HK, Ralfkiaer E. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:185-187.
15. Kiel MJ, Velusamy T, Betz BL, et al. Wholegenome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553-1565.
16. Nelson EA, Walker SR, Xiang M, et al. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012;3(7-8): 503-511.
17. Virgilio L, Isobe M, Narducci MG, et al. Chromosome walking on the TCL1 locus involved in T-cell neoplasia. Proc Natl Acad Sci USA. 1993;90(20):9275- 9279.
18. Soulier J, Madani A, Cacheux V, Rosenzwajg M, Sigaux F, Stern MH. The MTCP-1/c6.1B gene encodes for a cytoplasmic 8 kD protein overexpressed in T cell leukemia bearing a t(X;14) translocation. Oncogene. 1994;9(12):3565-3570.
19. Thick J, Sherrington PD, Fisch P, Taylor AM, Rabbitts TH. Molecular analysis of a new translocation, t(X;14)(q28;q11), in premalignancy and in leukaemia associated with ataxia telangiectasia. Genes Chromosomes Cancer. 1992;5(4):321-325.
20. Yuille MA, Coignet LJ, Abraham SM, et al. ATM is usually rearranged in T-cell prolymphocytic leukaemia. Oncogene. 1998;16(6):789-796.
21. Anderson AC, Kitchens EA, Chan SW, et al. The Notch regulator Numb links the Notch and TCR signaling pathways. J Immunol. 2005;174(2): 890-897.
22. Filen S, Lahesmaa R. GIMAP proteins in T-lymphocytes. J Signal Transduct. 2010;2010: 268589.
23. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118(11):3080-3087.
24. Jeong EG, Kim MS, Nam HK, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008;14(12): 3716-3721.
25. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.
26. Bergmann AK, Schneppenheim S, Seifert M, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2014;53(4):309-316.
27. Chen E, Staudt LM, Green AR. Janus kinase deregulation in leukemia and lymphoma. Immunity. 2012;36(4):529-541.
28. Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci. 2008;33(3):122-131.
29. Soulier J, Pierron G, Vecchione D, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31(3): 248-254.
30. Costa D, Queralt R, Aymerich M, et al. High levels of chromosomal imbalances in typical and smallcell variants of T-cell prolymphocytic leukemia. Cancer Genet Cytogenet. 2003;147(1):36-43.
31. Bug S, Dürig J, Oyen F, et al. Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition. Cancer Genet Cytogenet. 2009;192(1):44-47.
32. Nowak D, Le Toriellec E, Stern MH, et al. Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica. 2009;94(4): 518-527.
33. Saunders A, Webb LM, Janas ML, et al. Putative GTPase GIMAP1 is critical for the development of mature B and T lymphocytes. Blood. 2010; 115(16):3249-3257.
34. Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis. 2013;72(9):1510-1516.
35. Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer. 2007;7(12):925-936.
36. Khan SN, Jankowska AM, Mahfouz R, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 2013;27(6): 1301-1309.
37. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2): 181-185.
38. Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. JAK kinases overexpression promotes in vitro cell transformation. Oncogene. 2008;27(11):1511-1519.
39. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
40. Yamashita Y, Yuan J, Suetake I, et al. Arraybased genomic resequencing of human leukemia. Oncogene. 2010;29(25):3723-3731.
41. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7): 591-597.
42. Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol. 2012;19(8):754-759.
43. Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasaltype natural killer cell lymphoma. Leukemia. 2014; 28(2):338-348.
44. Yamada K, Ariyoshi K, Onishi M, et al. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol. 2000; 71(1):46-54.
45. Rajala HL, Eldfors S, Kuusanmäki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121(22):4541-4550.
46. Harir N, Pecquet C, Kerenyi M, et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood. 2007;109(4): 1678-1686.
47. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10(2):249-259.
48. Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12): 3421-3429.
49. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7): 480-490.
50. Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 2006;17(5):349-366.